Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM3 | Q14832 | 2/20 | 0.69 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.63 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.59 |
| ▸ | GCLC | P48506 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25500315 | 0.90 | GRM3 (0.73) | GRM3FOLH1NAALAD2GCLC | |
| SCHEMBL1377526 | 0.90 | GRM3 (0.73) | GRM3FOLH1NAALAD2GCLC | |
| SCHEMBL7609960 | 0.87 | FOLH1 (0.62) | GRM3FOLH1NAALAD2 | |
| SCHEMBL12145013 | 0.87 | GRM3 (0.73) | GRM3FOLH1NAALAD2 | |
| SCHEMBL5060255 | 0.85 | GRM3 (0.82) | GRM3FOLH1NAALAD2 | |
| SCHEMBL5051325 | 0.84 | GRM3 (0.81) | GRM3FOLH1NAALAD2 | |
| SCHEMBL20529841 | 0.84 | GRM3 (0.81) | GRM3FOLH1NAALAD2 | |
| SCHEMBL5483402 | 0.84 | GRM3 (0.69) | GRM3FOLH1NAALAD2 | |
| SCHEMBL5060080 | 0.83 | GRM3 (0.85) | GRM3FOLH1NAALAD2GCLC | |
| SCHEMBL1376163 | 0.83 | GRM3 (0.79) | GRM3FOLH1NAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250064948-A1 | GCPII INHIBITION FOR THE TREATMENT OF SARCOPENIA AND AGING | THE JOHNS HOPKINS UNIVERSITY | 2025-02-27 | — | — | US | claimed |
| WO-2023154939-A2 | GCPII INHIBITION FOR THE TREATMENT OF SARCOPENIA AND AGING | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-08-17 | — | — | WO | claimed |
| US-11167049-B2 | Organ protection in PSMA-targeted radionuclide therapy of prostate cancer | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2021-11-09 | — | — | US | claimed |
| EP-3193914-B1 | ORGAN PROTECTION IN PSMA-TARGETED RADIONUCLIDE THERAPY OF PROSTATE CANCER | MOLECULAR INSIGHT PHARM INC (US) | 2021-01-20 | — | — | EP | claimed |
| US-20200254120-A1 | ORGAN PROTECTION IN PSMA-TARGETED RADIONUCLIDE THERAPY OF PROSTATE CANCER | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2020-08-13 | — | — | US | claimed |
| US-10668174-B2 | Organ protection in PSMA-targeted radionuclide therapy of prostate cancer | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2020-06-02 | — | — | US | claimed |
| US-20180207299-A1 | ORGAN PROTECTION IN PSMA-TARGETED RADIONUCLIDE THERAPY OF PROSTATE CANCER | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2018-07-26 | — | — | US | claimed |
| US-9956305-B2 | Organ protection in PSMA-targeted radionuclide therapy of prostate cancer | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | claimed |
| EP-3193914-A1 | ORGAN PROTECTION IN PSMA-TARGETED RADIONUCLIDE THERAPY OF PROSTATE CANCER | Molecular Insight Pharmaceuticals, Inc. (US) | 2017-07-26 | — | — | EP | claimed |
| WO-2016040179-A1 | ORGAN PROTECTION IN PSMA-TARGETED RADIONUCLIDE THERAPY OF PROSTATE CANCER | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-03-17 | — | — | WO | claimed |
| EP-0954295-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-10 | — | — | EP | claimed |
| US-5977090-A | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-02 | — | — | US | claimed |
| EP-0949922-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-10-20 | — | — | EP | claimed |
| CN-1230889-A | NAALADase compositions and methods for treating glutamate abnormalities and for producing neuronal activity in animals | GUILFORD PHARM INC (US) | 1999-10-06 | — | — | CN | claimed |
| WO-1999033849-A1 | PRODRUGS OF NAALADASE INHIBITORS | GUILDFORD PHARMACEUTICALS INC. (US) | 1999-07-08 | — | — | WO | claimed |
| US-5880112-A | PHOSPHINIC ACID DERIVATIVES; PROSTATE CANCER TREATMENT | GUILFORD PHARMACEUTICALS INC. (US) | 1999-03-09 | — | — | US | claimed |
| WO-1998013044-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | claimed |
| WO-1998013046-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | claimed |
| WO-1997048399-A1 | CERTAIN PHOSPHINYL DERIVATIVES USEFUL AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | claimed |
| WO-1997048409-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207299-A1 | ORGAN PROTECTION IN PSMA-TARGETED RADIONUCLIDE THERAPY OF PROSTATE CANCER | FOLH1, SHBG, KLK3 | GRM3 3265/4885FOLH1 1/4885NAALAD2 121/4885 |
| US-10668174-B2 | Organ protection in PSMA-targeted radionuclide therapy of prostate cancer | FOLH1, SHBG, KLK3 | GRM3 3265/4885FOLH1 1/4885NAALAD2 121/4885 |
| US-20250064948-A1 | GCPII INHIBITION FOR THE TREATMENT OF SARCOPENIA AND AGING | DGKI, PGC, MPC2 | GRM3 384/4885FOLH1 149/4885NAALAD2 572/4885 |
| US-11167049-B2 | Organ protection in PSMA-targeted radionuclide therapy of prostate cancer | FOLH1, SHBG, KLK3 | GRM3 3265/4885FOLH1 1/4885NAALAD2 121/4885 |
| US-20200254120-A1 | ORGAN PROTECTION IN PSMA-TARGETED RADIONUCLIDE THERAPY OF PROSTATE CANCER | FOLH1, SHBG, KLK3 | GRM3 3265/4885FOLH1 1/4885NAALAD2 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.